Wealthfront Inc. lifted its stake in Eli Lilly and Co (NYSE:LLY) by 22.5% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 29,246 shares of the company’s stock after buying an additional 5,370 shares during the quarter. Wealthfront Inc.’s holdings in Eli Lilly and were worth $2,470,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Pathstone Family Office LLC grew its position in shares of Eli Lilly and by 100.0% during the second quarter. Pathstone Family Office LLC now owns 58 shares of the company’s stock worth $4,774,000 after purchasing an additional 29 shares in the last quarter. Vantage Financial Partners Ltd. Inc. purchased a new stake in shares of Eli Lilly and during the second quarter worth about $494,000. Gradient Investments LLC purchased a new stake in shares of Eli Lilly and during the fourth quarter worth about $103,000. Acrospire Investment Management LLC grew its position in shares of Eli Lilly and by 16.7% during the second quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock worth $115,000 after purchasing an additional 200 shares in the last quarter. Finally, MPS Loria Financial Planners LLC purchased a new stake in shares of Eli Lilly and during the second quarter worth about $128,000. 75.71% of the stock is currently owned by hedge funds and other institutional investors.
Several research firms recently issued reports on LLY. BMO Capital Markets set a $73.00 target price on Eli Lilly and and gave the stock a “sell” rating in a research report on Tuesday, December 5th. Credit Suisse Group reiterated a “hold” rating and set a $80.00 target price on shares of Eli Lilly and in a research report on Friday, February 2nd. Leerink Swann increased their target price on Eli Lilly and from $92.00 to $93.00 and gave the stock a “market perform” rating in a research report on Monday, October 23rd. Argus upgraded Eli Lilly and from a “hold” rating to a “buy” rating and increased their target price for the stock from $85.52 to $115.00 in a research report on Friday, January 5th. Finally, Goldman Sachs Group cut Eli Lilly and from a “buy” rating to a “neutral” rating and increased their target price for the stock from $86.98 to $95.00 in a research report on Tuesday, January 16th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $92.02.
Eli Lilly and Co (NYSE:LLY) opened at $77.40 on Tuesday. The firm has a market capitalization of $86,950.00, a P/E ratio of 49.05, a price-to-earnings-growth ratio of 1.47 and a beta of 0.23. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.03 and a current ratio of 1.38. Eli Lilly and Co has a 1-year low of $73.69 and a 1-year high of $89.09.
Eli Lilly and (NYSE:LLY) last announced its earnings results on Wednesday, January 31st. The company reported $1.14 EPS for the quarter, topping the Zacks’ consensus estimate of $1.08 by $0.06. The firm had revenue of $6.16 billion during the quarter, compared to analysts’ expectations of $5.93 billion. Eli Lilly and had a positive return on equity of 31.44% and a negative net margin of 0.89%. The company’s quarterly revenue was up 7.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.95 EPS. equities research analysts expect that Eli Lilly and Co will post 4.87 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, March 9th. Stockholders of record on Thursday, February 15th will be issued a $0.5625 dividend. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.52. The ex-dividend date is Wednesday, February 14th. This represents a $2.25 dividend on an annualized basis and a dividend yield of 2.91%. Eli Lilly and’s payout ratio is 139.75%.
In other news, insider Donald A. Zakrowski sold 900 shares of Eli Lilly and stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $81.09, for a total value of $72,981.00. Following the completion of the transaction, the insider now owns 4,130 shares in the company, valued at approximately $334,901.70. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Jeffrey N. Simmons sold 9,625 shares of Eli Lilly and stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $81.12, for a total value of $780,780.00. Following the completion of the transaction, the senior vice president now owns 152,120 shares of the company’s stock, valued at approximately $12,339,974.40. The disclosure for this sale can be found here. In the last quarter, insiders sold 259,610 shares of company stock valued at $22,727,406. Company insiders own 0.20% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Wealthfront Inc. Buys 5,370 Shares of Eli Lilly and Co (LLY)” was originally published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.thelincolnianonline.com/2018/02/20/wealthfront-inc-buys-5370-shares-of-eli-lilly-and-co-lly.html.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.